Alteration in TWIST Expression: Possible Role in Paclitaxel-induced Apoptosis in Human Laryngeal Carcinoma Hep-2 Cell Line

Liang Yu; Hui-zheng Li; Su-mei Lu; Wen-wen Liu; Jian-feng Li; Hai-bo Wang; Wei Xu
December 2009
Croatian Medical Journal;Dec2009, Vol. 50 Issue 6, p536
Academic Journal
Aim To explore the relationship between alteration in the expression of TWIST, highly conserved transcription factor from the basic helix-loop-helix family, and apoptosis of Hep-2 cells induced by chemotherapeutic agent paclitaxel. Methods Morphological changes of Hep-2 cells were observed by acridine orange cytochemistry staining. Viability of Hep-2 cells treated with various concentrations of paclitaxel was examined by cell proliferation assay. Apoptosis was examined by flow cytometry. The mRNA and protein expression of TWIST in response to paclitaxel at 24 hours, 48 hours, and 72 hours was examined by reverse transcription- polymerase chain reaction (RT-PCR) and Western blotting, respectively. Results Typical morphological changes of apoptotic cells at 24 hours, 48 hours, or 72 hours after treatment wiyth paclitaxel (10 × 10-9 mol/L) were observed. The cell survival rates significantly decreased in a concentration- and time-dependent manner (P = 0.001). Paclitaxel-induced apoptosis increased with culture time (22.6 ± 5.3% after 24 hours, 38.7 ± 7.9% after 48 hours, and 52.4 ± 14.3% after 72 hours; P = 0.002). Both mRNA and protein expression of TWIST was markedly decreased at both mRNA levels and protein levels, at 24 hours, 48 hours, and 72 hours in the paclitaxelinduced apoptosis of Hep-2 cells (P < 0.001). Conclusion TWIST, which has a significantly decreased expression in response to paclitaxel in Hep-2 cells, may play a pivotal role in paclitaxel-induced apoptosis of Hep-2 cells.


Related Articles

  • Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer. Jong Gwang Kim; Sang Kyun Sohn; Hong Suk Song; Ki-Young Kwon; Young Rok Do; Kyung Hee Lee; Myung Soo Hyun; Hun Mo Ryoo; Sung Hwa Bae; Keon Uk Park; Jin Ho Baek; Won Sik Lee; Joo Seop Chung; Goon Jae Cho; Chang-Hak Sohn; Jung Soon Jang; Ho Young Chung; Wansik Yu // Cancer Chemotherapy & Pharmacology;Dec2007, Vol. 60 Issue 6, p863 

    Since a weekly administration of paclitaxel has demonstrated a sustained efficacy and more favorable toxicity profile than a 3-weekly administration for various solid tumors, the present study was conducted to evaluate the efficacy and safety of a combination regimen of weekly paclitaxel plus...

  • GDF3 inhibits the growth of breast cancer cells and promotes the apoptosis induced by Taxol. Li, Qiang; Ling, Yichen; Yu, Long // Journal of Cancer Research & Clinical Oncology;Jun2012, Vol. 138 Issue 6, p1073 

    Purpose: The aim of this study is to investigate whether GDF3 is related to the progression of human breast cancer and the effects of GDF3 on breast cancer cells. Methods: The expression of GDF3 in 24 breast cancer specimens paired with corresponding neighboring nontumorous tissue was studied by...

  • Weekly Paclitaxel in Elderly Patients with Advanced Breast Cancer: A Dose-Finding Study. Repetto, Lazzaro; Comandini, Danila; Mammoliti, Sonia; Pietropaolo, Maria; Mastro, Lucia Del // Drugs in R&D;2004, Vol. 5 Issue 1, p11 

    Presents a study on the use of paclitaxel in elderly patients with advanced breast cancer. Highest rate of incidence and mortality for cancer in women in Europe; Benefit of chemotherapy in elderly patients with breast cancer; Aspects of efficacy and tolerability of chemotherapy; Criteria of...

  • Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. Chen, X. S.; Nie, X. Q.; Chen, C. M.; Wu, J. Y.; Wu, J.; Lu, J. S.; Shao, Z. M.; Shen, Z. Z.; Shen, K. W. // Annals of Oncology;May2010, Vol. 21 Issue 5, p961 

    Background: To evaluate the activity and safety of nonanthracycline-containing weekly PCb [paclitaxel (Taxol) plus carboplatin] regimen in neoadjuvant treatment of breast cancer.

  • In vivo establishment and characterization of a paclitaxel-resistant human ovarian cancer cell line showing enhanced growth properties and drug-resistance only in vivo. Okugawa, Kaoru; Kobayashi, Hiroaki; Hirakawa, Toshio; Sonoda, Takanori; Ogura, Tomonori; Nakano, Hitoo // Journal of Cancer Research & Clinical Oncology;Mar2004, Vol. 130 Issue 3, p178 

    Purpose. In order to establish a more faithful model of clinically recurrent ovarian cancer after paclitaxel-based chemotherapy, a paclitaxel-resistant human ovarian cancer cell line was established in vivo, and its biological profiles were compared with the conventional in vitro established...

  • Paclitaxel in Early Breast Cancer: A Viewpoint by David A. Cameron. Cameron, David A. // Drugs;2004, Vol. 64 Issue 16, p1848 

    Paclitaxel was the first of a new class of anti-cancer agents to be available for use in advanced and now, more recently, early-stage breast cancer. It has undoubtedly made a difference to lives of many women with breast cancer and continues to do so today. Like most cytotoxics it causes...

  • Differential gene expression in a paclitaxel-resistant clone of a head and neck cancer cell line. Schmidt, Marianne; Schler, Gabriele; Gruensfelder, Petra; Hoppe, Florian // European Archives of Oto-Rhino-Laryngology;Feb2006, Vol. 263 Issue 2, p127 

    The anti-neoplastic drug paclitaxel (taxol), which is known to block cells in the G2/M phase of the cell cycle through stabilization of microtubules, is meanwhile commonly used for chemotherapy of advanced head and neck cancer. Chemotherapy is primarily used in order to preserve laryngeal and/or...

  • Combining Paclitaxel with ABT-263 Has a Synergistic Effect on Paclitaxel Resistant Prostate Cancer Cells. Wang, Chihuei; Huang, Shih-Bo; Yang, Min-Chi; Lin, Yi-Tsen; Chu, I-Hung; Shen, Ya-Ni; Chiu, Yueh-Ho; Hung, Shao-Hung; Kang, Lin; Hong, Yi-Ren; Chen, Chung-Hwan // PLoS ONE;Mar2015, Vol. 10 Issue 3, p1 

    We assessed the capability of paclitaxel, one of the taxanes, to induce death in two prostate cancer lines, LNCaP and PC3. Paclitaxel drove an apoptotic pathway in LNCaP, but not in PC3 cells, in response to G2/M arrest. An examination of the levels of anti-apoptotic proteins revealed that...

  • Taxol-induced apoptosis in human SKOV3 ovarian and MCF7 breast carcinoma cells is caspase-3 and caspase-9 independent. Ofir, R.; Seidman, R.; Rabinski, T.; Krup, M.; Yavelsky, V.; Weinstein, Y.; Wolfson, M. // Cell Death & Differentiation;Jun2002, Vol. 9 Issue 6, p636 

    Taxol is used in chemotherapy regimens against breast and ovarian cancer. Treatment of tumor model cell lines with taxol induces apoptosis, but exact mechanism is not sufficiently understood. Our results demonstrate that in response to taxol, various cell types differentially utilize distinct...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics